Novo Nordisk A/S (NOVO-B) Stock Price & News

Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia

About Novo Nordisk A/S

CEOMaziar Mike Doustdar

Employees66.7 мян

Founded1923

HeadquartersBagsværd, Capital Region of Denmark, Дани

SectorPharmaceutical industry

Websitenovonordisk.com

Revenue

Net income

All values in DKK	2025 оны 9-р сар	2025 оны 12-р сар	2026 оны 3-р сар	2026 оны 6-р сар
Revenue	74.98 тэрбум	79.14 тэрбум	96.82 тэрбум	78.49 тэрбум
Cost of goods sold	14.47 тэрбум	14.17 тэрбум	13.60 тэрбум	17.10 тэрбум
Cost of revenue	14.47 тэрбум	14.17 тэрбум	13.60 тэрбум	17.10 тэрбум
Research and development expenses	11.49 тэрбум	12.67 тэрбум	10.28 тэрбум	11.46 тэрбум
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	15.76 тэрбум	17.14 тэрбум	13.22 тэрбум	16.31 тэрбум
Operating expense	27.25 тэрбум	29.73 тэрбум	23.61 тэрбум	28.00 тэрбум
Total operating expenses	41.72 тэрбум	43.90 тэрбум	37.20 тэрбум	45.10 тэрбум
Operating income	33.25 тэрбум	35.24 тэрбум	59.62 тэрбум	33.39 тэрбум
Other non operating income	1.53 тэрбум	-241.00 сая	-	-
EBT including unusual items	25.52 тэрбум	34.18 тэрбум	62.17 тэрбум	26.88 тэрбум
EBT excluding unusual items	35.09 тэрбум	37.62 тэрбум	62.17 тэрбум	33.20 тэрбум
Income tax expense	5.51 тэрбум	7.29 тэрбум	13.62 тэрбум	5.89 тэрбум
Effective tax rate	21.60%	21.34%	21.90%	21.90%
Other operating expenses	-	-81.00 сая	106.00 сая	234.00 сая
Net income	20.01 тэрбум	26.89 тэрбум	48.56 тэрбум	20.99 тэрбум
Net profit margin	26.68%	33.98%	50.15%	26.74%
Earnings per share	4.50	6.04	6.63	6.18
Interest and investment income	307.00 сая	4.41 тэрбум	-	1.31 тэрбум
Interest expense	-	-4.97 тэрбум	-	-1.50 тэрбум
Net interest expenses	307.00 сая	-560.00 сая	-	-186.00 сая
Depreciation and amortization charges	-	-	-	-
EBITDA	36.49 тэрбум	36.66 тэрбум	63.13 тэрбум	36.99 тэрбум
Gain or loss from assets sale	-	-	-	-

Ask anything